an elder woman with gray and white hair is wearing a blue coat and teal backpack with gray straps while gazing off to the left.

About Us

Seres’ visionary team has been at the forefront of microbiome therapeutics for over a decade.

Pioneering microbiome therapeutics for serious diseases

Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome.

We are an exceptional team of drug development and microbiome experts. Our leadership team, Board of Directors and Scientific Advisory Board have vast experience in the discovery, development, regulatory approval and successful commercialization of a wide range of therapeutic products.

Our mission is to transform the lives of patients worldwide with revolutionary microbiome therapeutics.

Our leadership
team

  • Eric Shaff is the President and Chief Executive Officer of Seres. Mr. Shaff was previously the Executive Vice President, Chief Operating and Financial Officer of Seres. He has over 20 years of experience working in leadership roles in biotechnology finance, corporate development and capital markets. Mr. Shaff also serves on the board of directors of Sigilon Therapeutics, Inc. Prior to joining Seres, he was Vice President, Corporate Finance, at Momenta Pharmaceuticals, where he helped manage Momenta’s accounting, finance, planning and procurement functions, as well as contributing to Momenta’s investor relations efforts. Prior to joining Momenta, Mr. Shaff was Vice President, Finance, of Genzyme’s Rare Genetic Disease Division, responsible for a global portfolio of products. Mr. Shaff held several positions at Genzyme in business unit finance, corporate finance and corporate development. Prior to Genzyme, Mr. Shaff worked in corporate finance at Pfizer and worked in investment banking for Broadview International (now Jefferies LLC). Mr. Shaff earned his B.A. from the University of Pennsylvania in political science and economics and his MBA with a concentration in finance from the Johnson Graduate School of Management at Cornell University.

  • John Auniņš is the Executive Vice President of Bioprocess & Manufacturing and the Chief Technology Officer of Seres. He has more than 30 years of experience in the biotechnology industry, with a focus in bioprocess development, manufacturing support and project leadership. Prior to joining Seres, he led process and product development teams at Merck Research Laboratories for Vaqta®, Varivax®, Zostavax®, ProQuad®, Rotateq® and Gardasil® vaccines. The Vaqta (Hepatitis A virus) and Gardasil (Human Papilloma Virus) process teams were awarded with American Chemical Society’s Industrial Biotechnology Award for innovation, contribution to bioengineering and societal impact. He is a Fellow of the American Institute for Medical and Biological Engineering, and an adjunct Full Professor at the Instituto de Tecnologia Química e Biológica (ITQB) in Oeiras, Portugal. He has authored over 60 articles and book chapters, and has chaired six international conferences in vaccines and bioprocess technology. He is on the Scientific Advisory Boards of Rubius Therapeutics, Ring Therapeutics, and the Instituto de Biologia Experimental e Tecnológica, in Oeiras, Portugal. Dr. Auniņš earned his Ph.D. in chemical engineering from MIT in 1989 under Institute Professor Daniel I.C. Wang.

  • Kelly Brady is the Vice President of Clinical Operations of Seres. Throughout her 13-year career she has held positions of increasing responsibility in clinical operations and clinical program management. Prior to joining Seres, Ms. Brady was Senior Director and Global Clinical Program Lead at Akebia, where she oversaw pivotal programs in anemia due to chronic kidney disease. She also previously held roles in Operations and Program management at Acetylon, where she worked on the company’s acquisition by Celgene. Prior to Acetylon, she was the Global Phase 3 Clinical Operations Leader at Millennium Pharmaceuticals, Takeda Oncology Company, overseeing the Adcetris trials in Hodgkins Lymphoma across 29 countries. She also worked as a member of the operations team at Osiris Therapeutics, managing global GvHD studies and working on Prochymal, the first stem cell therapy approved in Canada for acute GvHD in children. Ms. Brady holds a Bachelor’s degree in neuroscience from Lafayette College and a Master’s degree in biotechnology from Johns Hopkins University.

  • Marcus Chapman is Senior Vice President, Principal Financial and Accounting Officer of Seres. Mr. Chapman has two decades of experience within the biopharmaceutical industry. Before joining Seres, he served as Senior Director of Finance and Interim Head of Finance at Takeda Oncology. In these roles, Mr. Chapman oversaw finance functions supporting U.S. sales, U.S. and global marketing, operations, global medical affairs and manufacturing. Prior to Takeda, he held senior roles at Clarion Healthcare Consulting and Strategic Decisions Group. He began his career at LaSalle Partners in their Investment Banking and Investment Management groups. Mr. Chapman received his B.A. in economics from Wheaton College and his MBA from The Tuck School at Dartmouth.

  • Gloria Cosgrove is Vice President, Quality Systems (GxP Quality Assurance and Quality Control) of Seres. She has over 30 years of drug development experience in the biopharmaceutical industry and as a leader in Quality. Prior to joining Seres, she held leadership positions within quality at Synageva BioPharma, Regeneron and Boehringer Ingelheim, specializing in process development/ improvement, GxP quality management, training and preparation and conduct of regulatory inspections from global regulatory agencies, including the FDA, EU, MHRA, Health Canada and PMDA in Japan. In addition to her role at Seres, Ms. Cosgrove serves as President of a small non-profit Board in Connecticut. She received her Bachelor’s degree in special education and psychology from Utah State University.

  • Thomas J. DesRosier is the Executive Vice President, Chief Legal Officer and Secretary of Seres. He brings more than 30 years of experience in the biopharmaceutical industry. Prior to joining Seres, he served as Chief Legal and Administrative Officer at ARIAD Pharmaceuticals, and prior to that held the same position at Cubist Pharmaceuticals where he led the negotiation of the acquisition of Cubist by Merck. Previous to that, he served as Senior Vice President and General Counsel, North America of Sanofi, a position he assumed in 2011 after Sanofi acquired Genzyme Corporation, where he was Senior Vice President and Chief Legal Officer. Prior to his 12-year tenure at Genzyme, Mr. DesRosier held senior legal positions at Wyeth Pharmaceuticals, predecessor Genetic Institute, and E.I. DuPont de Nemours. He received his B.A. in chemistry from the University of Vermont and his J.D. from Wake Forest University School of Law. Mr. DesRosier serves as a director on the board of Avanir Pharmaceuticals where he is Chairman of both the Audit Committee and Compliance Committee.

  • Matthew Henn is the Executive Vice President and Chief Scientific Officer of Seres. He has over 20 years of combined research experience in microbial ecology, genomics and bioinformatics that spans both environmental and human disease applications. He has been involved in the discovery and clinical development of multiple microbiome therapeutics including all of Seres’ product candidates and has authored over 65 peer-reviewed publications. His research has focused on microbial physiology and the functional role of microbes in both environmental and human disease applications, and on the development of genomic and functional tools to study microbial systems. Prior to helping launch Seres in 2012, he was the Director of Viral Genomics and Assistant Director of the Genome Sequencing Center for Infectious Diseases at the Broad Institute of MIT and Harvard.  He has served on various NIH working groups on antimicrobial resistance and microbiome research, as a scientific advisor for the National Institutes of Health’s Viral Pathogen Bioinformatics Resource Center, and as an ad-hoc reviewer and editor of various peer-reviewed journals.  He currently serves on the Scientific Advisory Board of Growcentia, Inc., an agricultural microbiome company. Dr. Henn earned his Ph.D. from the University of California at Berkeley, where he was a NASA Earth Systems Sciences Fellow, and trained as an NSF Postdoctoral Fellow at Duke University.

  • Barbara McGovern is VP, Medical Affairs of Seres. Dr. McGovern has over 25 years of experience in infectious diseases. Prior to joining Seres, she served as Medical Director in the Medical Affairs Division at AbbVie and helped to launch Viekera Pak for treatment of Hepatitis C virus (HCV) infection. At AbbVie, Dr. McGovern was recipient of the 2015 President’s Award in recognition of successful execution of 7 major publications in the New England Journal of Medicine, Lancet and JAMA. As an academic clinician at Tufts Medical Center, she also authored more than 50 journal articles, editorials and textbook chapters on HIV and HCV and was an Associate Editor of Clinical Infectious Diseases and a Deputy Editor at UpToDate. Dr. McGovern has also served as a member of the Antiviral Advisory Committee for FDA and as a panel guideline member for the Department of Health and Human Services on HIV, Hepatitis C and Hepatitis B virus infections. She earned her undergraduate degree from Queens College, CUNY, her M.D. at Albert Einstein College of Medicine and completed her internship, residency and infectious disease fellowship at Tufts Medical Center, where she remained on faculty for many years.

  • Carlo Tanzi joined Seres in November 2015 as Head of Investor Relations and Corporate Communications. His biotechnology industry experience includes roles in finance, program management, corporate development and investor relations. Dr. Tanzi joined Seres from Biogen where he held roles in the Finance and Corporate Development groups, including as the Program Management Lead for the Tysabri® and Tecfidera® programs. Dr. Tanzi was previously a healthcare management consultant with Health Advances. He earned a B.A. in biology from the University of Rochester and a Ph.D. in cell and molecular biology from the University of Pennsylvania. Dr. Tanzi has been a member of the National Investor Relations Institute (NIRI) since 2013, and he is a Director for the Boston Chapter of NIRI.

  • Jim Weston is the Senior Vice President and Head of Regulatory Affairs at Seres. He previously headed the regulatory function for Oxyrane Ltd., and prior to that led the CMC Regulatory Group at Shire HGT, where he was instrumental in the expansion of their marketed products into new markets and development of investigational products. Previously, he was a senior consultant at BioBridges LLC and Talaris Advisors where he provided strategic regulatory expertise to many small and mid-sized development companies. He was also the Senior Vice President of Regulatory Affairs and Quality for Alseres Pharmaceuticals, directing the regulatory strategies for candidates in Parkinson’s disease, Dementia and Spinal Cord Injury. Before Alseres, Mr. Weston was Vice President Corporate and Regulatory Strategy and Managing Director of Cato Research, Boston. He also held Senior Regulatory Affairs and Government Relations management positions with Biopure and Regulatory, Clinical Research, Quality Assurance and Quality Control management positions at DuPont Pharmaceuticals. Mr. Weston is a veteran regulatory affairs and quality executive with a demonstrated ability to spearhead the drug development process by crafting effective regulatory and clinical strategies worldwide, including the U.S., Canada, Europe (centralized and member states), Australia and Japan. His knowledge of domestic and international regulatory requirements and his close interactions with regulatory authorities have resulted in successful and timely implementation of clinical trial programs and integrated regulatory submissions, including investigational and marketing applications that resulted in the approval of more than 11 drugs/biologics worldwide. Mr. Weston has a B.A. in biological sciences degree from Rutgers College and an MBA from Northeastern University.

  • Lisa von Moltke, M.D., is the Chief Medical Officer at Seres. She has extensive experience in directing successful development programs, leading clinical teams and interacting with regulatory agencies across multiple areas of medicine. Prior to joining Seres, Dr. von Moltke worked for Alkermes, Inc., where she served in roles of increasing seniority, culminating as Senior Vice President and Head of Clinical Development. Prior to joining Alkermes, Dr. von Moltke served as Vice President Clinical Pharmacology at Sanofi/Genzyme Corporation, where she also served as U.S. Head Clinical & Exploratory Pharmacology Sciences (CEP) and Early Development and later as Head CEP for Japan and China regions. Earlier in her career, Dr. von Moltke served as Head, Translational Medicine for the Takeda Oncology Company. She has served as President of the American College of Clinical Pharmacology and as the Editor-in-Chief of The Journal of Clinical Pharmacology. Dr. von Moltke earned a B.A. at Wellesley College and her M.D. from Michigan State University, College of Human Medicine.

  • Jennifer Russo Wortman is the Vice President of Clinical Discovery and Research Technology at Seres, overseeing multi-omic microbiome data generation, algorithm development and integrative data analysis, as well as the computational infrastructure supporting our reverse translation platform. Prior to joining Seres, Ms. Wortman was the Director of Microbial Informatics at the Broad Institute, responsible for the software development and analytical strategies supporting the NIAID-funded Genome Center for Infectious Diseases (GCID). That followed three years as Associate Director of Bioinformatics at the Institute for Genome Sciences (IGS) at the University of Maryland School of Medicine, where she was the co-Principal Investigator of the Human Microbiome Project’s Data Analysis and Coordination Center (HMP DACC). She has over 70 peer-reviewed publications and has made significant contributions to the published genome analyses of humans, mice, fruit fly and mosquito as well as diverse pathogenic fungi, parasites and bacteria. Ms. Wortman holds an M.S. in biochemistry from the University of North Carolina, Chapel Hill.

  • Jeff York joined Seres in 2014 and brings over 20 years of experience helping organizations and individuals adapt to periods of growth, mergers and significant changes. Most recently, Mr. York served in various HR leadership roles at Millennium Pharmaceuticals (later Takeda) since 2002. Navigating through massive restructuring, product divestiture, a CEO/leadership transition, and then ultimately launching a drug, Mr. York helped build a culture that allowed Millennium to become a perennial leader among Fortune magazine’s 100 Best Companies to Work For. Prior to Millennium, Mr. York was a Senior Business Partner for PTC, driving HR strategy in support of a global engineering software business with offices in over 30 countries. Mr. York earned his B.S. degree from Indiana University and his M.S. degree in industrial/organizational psychology from Springfield College.

  • Terri Young is the Executive Vice President, Chief Commercial and Strategy Officer at Seres Therapeutics. Prior to joining Seres, Dr. Young served as Vice President, Global Commercial Strategy at Sage Therapeutics, where she led development of Sage’s global commercial capabilities, including global marketing, insights and analytics and new product planning. Previously, she held commercial leadership roles of increasing responsibility at Bristol-Myers Squibb, culminating in her role as Vice President and General Manager, Cardiovascular, in which she led the global ELIQUIS® business to become the company’s largest product by revenue. Earlier in her career, Dr. Young held marketing and sales roles at GlaxoSmithKline, where she catalyzed growth for the company’s Urology, Diabetes and NeuroHealth organizations. Dr. Young received her B.S. in pharmacy and her Ph.D. in healthcare marketing from the University of South Carolina. Dr. Young is a member of the Women in Bio and Healthcare Businesswomen’s Association, and served on the Advisory Board of the Healthcare Businesswomen’s Association.

Board
of Directors

  • Eric Shaff

    President, Chief Executive Officer

    Eric Shaff is the President and Chief Executive Officer of Seres. Mr. Shaff was previously the Executive Vice President, Chief Operating and Financial Officer of Seres. He has over 20 years of experience working in leadership roles in biotechnology finance, corporate development and capital markets. Mr. Shaff also serves on the board of directors of Sigilon Therapeutics, Inc. Prior to joining Seres, he was Vice President, Corporate Finance, at Momenta Pharmaceuticals, where he helped manage Momenta’s accounting, finance, planning and procurement functions, as well as contributing to Momenta’s investor relations efforts. Prior to joining Momenta, Mr. Shaff was Vice President, Finance, of Genzyme’s Rare Genetic Disease Division, responsible for a global portfolio of products. Mr. Shaff held several positions at Genzyme in business unit finance, corporate finance and corporate development. Prior to Genzyme, Mr. Shaff worked in corporate finance at Pfizer and worked in investment banking for Broadview International (now Jefferies LLC). Mr. Shaff earned his B.A. from the University of Pennsylvania in political science and economics and his MBA with a concentration in finance from the Johnson Graduate School of Management at Cornell University.

  • Stephen Berenson

    Chairman of the Board of Directors

    Stephen Berenson is a Managing Partner at Flagship Pioneering and member of the firm’s Resource Allocation and Management Committees. Prior to Flagship, Mr. Berenson spent over three decades in various roles as an investment banker at J.P. Morgan. During his last 12 years at J.P. Morgan, Mr. Berenson was Vice Chairman of Investment Banking. He was also co-founder of J.P. Morgan’s Global Strategic Advisory Council and co-founder of the firm’s Board Initiative. Mr. Berenson currently also serves on the board of directors of Moderna, Inc. and CiBO Technologies, Inc. Mr. Berenson earned his S.B. in mathematics from the Massachusetts Institute of Technology.

  • Dennis Ausiello, M.D.

    Jackson Professor of Clinical Medicine at Harvard Medical School; Chair of Medicine, Emeritus at Massachusetts General Hospital

    Dennis A. Ausiello is the Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School. He is concurrently the Director, Emeritus of the Harvard Medical School’s M.D./Ph.D. Program. Dr. Ausiello is also Chair of Medicine, Emeritus, and Director of the Center for Assessment Technology and Continuous Health (CATCH) at Massachusetts General Hospital.  Dr. Ausiello was the former Lead Director of the board of directors at Pfizer, Inc. Previously, Dr. Ausiello served as an editor of Cecil’s Textbook of Medicine. He received his B.S. from Harvard College and his M.D. from the University of Pennsylvania School of Medicine. Throughout his career, Dr. Ausiello has made substantial contributions to the study of epithelial biology in the areas of membrane protein trafficking, ion channel regulation and signal transduction, and has published numerous articles, book chapters and textbooks.

  • Grégory Behar

    CEO, Nestlé Health Science

    Greg Behar is the Chief Executive Officer of Nestlé Health Science. Prior to this role, he was President and Chief Executive Officer of Boehringer Ingelheim Pharmaceuticals Inc. (USA). Mr. Behar has also previously served as Corporate Vice President Region North European Union, Canada and Australasia (NECAR) at Boehringer-Ingelheim GmbH. He received his B.S. from the University of California, Los Angeles, his M.S. in mechanical engineering and manufacturing from EPFL, in Switzerland, and his MBA from INSEAD, in France.

  • Kurt Graves

    Chairman, President and CEO, Intarcia Therapeutics, Inc.

    Kurt Graves is the Chairman, President and Chief Executive Officer of Intarcia. Prior to joining Intarcia, Mr. Graves was EVP, Chief Commercial Officer and Head of Corporate and Strategic Development at Vertex Pharmaceuticals. Prior to his tenure at Vertex, he spent nearly 10 years at Novartis Pharmaceuticals, most recently as Global Head of the General Medicines Business & Chief Marketing Officer for the Pharmaceuticals division. Mr. Graves also previously held several commercial and general management positions at Merck and Astra Merck/Astra Pharmaceuticals, where he spent most of his time leading the GI Business Unit responsible for Prilosec and Nexium. Mr. Graves earned his B.S. in biology from Hillsdale College and has attended executive leadership programs at Harvard University, the University of Pennsylvania Wharton School of Management and University of Michigan.

  • Paul Biondi

    Executive Partner, Flagship Pioneering

    Paul Biondi serves as Executive Partner at Flagship Pioneering where he has been since November, 2019. Mr. Biondi joined Flagship Pioneering following a seventeen-year tenure at Bristol-Myers Squibb (BMS) where he was most recently the Senior Vice President of Strategy and Business Development. Prior to serving in the role of Senior Vice President of Strategy, from 2002 to 2015, Mr. Biondi held a series of other leadership roles within BMS’ Research and Development organization overseeing strategy, portfolio and project management, as well as clinical and business operations.  Mr. Biondi holds a bachelor’s degree from Dartmouth College and an MBA from the J.L. Kellogg School of Management at Northwestern University.

  • Richard Kender

    Former Senior Vice President of Business Development and Corporate Licensing, Merck

    Richard Kender most recently served as Senior Vice President of Business Development and Corporate Licensing at Merck. Mr. Kender spent his entire professional career at the company in various corporate roles of increasing responsibility. At Merck, Mr. Kender was involved in more than 100 business development and licensing transactions. Currently, he also serves on the Board of Directors of Poxel, Bicycle Therapeutics PLC and ReViral Ltd.  He has previously served on the Boards of Directors of INC Research Holdings, Inc., Abide Therapeutics and FoxHollow Technologies Inc. Mr. Kender earned his B.S. in accounting from Villanova University and his MBA from Fairleigh Dickinson University.

  • Willard Dere, M.D. FACP

    Associate Vice President of Research, University of Utah Health Sciences, Professor of Internal Medicine

    Willard H. Dere, M.D., joined the University of Utah Health Sciences Center in November 2014 as the Executive Director of Personalized Health and Professor of Internal Medicine. He currently serves roles as Associate Vice President for Research, co-director of the Utah Center for Clinical and Translational Science, and co-director of the Center for Genomic Medicine. Prior to rejoining academia, Dr. Dere was in the biopharmaceutical industry for 25 years, first at Eli Lilly, then at Amgen, where he was most recently Head of Global Development and Chief Medical Officer. Dr. Dere led the clinical development of raloxifene, rPTH 1-34, denosumab, and other drugs in a broad range of therapeutic areas. Dr. Dere received his undergraduate and medical degrees from the University of California, Davis. He was awarded the 2008 Transformational Leadership Award from UC Davis School of Medicine, multiple teaching awards from the University of Utah School of Medicine, and is a fellow in the American College of Physicians.

  • Meryl Zausner

    Former Executive Vice President and Chief Financial Officer, Novartis Pharmaceuticals

    Meryl Zausner previously served as Chief Financial and Administrative Officer of Novartis Pharmaceuticals Corporation and was a member of the U.S. Pharmaceutical Executive Committee and Global Finance Leadership Team. At Novartis, she was instrumental in the launch of the Oncology Business Unit, as well as the company’s shared services organization. Currently she serves as a Board Member and Chair of the Audit Committee for both Neon Therapeutics, Inc. and the Multiple Myeloma Research Foundation. Ms. Zausner received a B.S. in accounting and economics from the University at Albany, SUNY.

Scientific
advisory board

  • Elhanan Borenstein, Ph.D.

    Associate Professor of Computer Science and of Medicine, Tel Aviv University

  • Charles Cooney, Ph.D.

    Emeritus Professor, Massachusetts Institute of Technology

  • Andrew Goodman, Ph.D.

    C.N.H. Long Professor of Microbial Pathogenesis and Director of the Microbial Sciences Institute, Yale University

  • Stephen Hanauer, M.D.

    Clifford Joseph Barborka Professor, Professor of Medicine (Gastroenterology and Hepatology), Northwestern Medicine, Feinberg School of Medicine

  • Curtis Huttenhower, Ph.D.

    Professor of Computational Biology and Bioinformatics, Department of Biostatistics, School of Public Health, Harvard University

  • Robert Jenq, M.D.

    Medical Oncologist; Assistant Professor at MD Anderson Cancer Center

  • William Sandborn, M.D.

    Director, Inflammatory Bowel Disease Center; Chief, Division of Gastroenterology; Professor of Medicine, UC San Diego Health

  • Marcel van den Brink, M.D., Ph.D.

    Head, Division of Hematologic Malignancies; Alan N. Houghton Professor in Immunology; Member, Memorial Sloan-Kettering Cancer Center

  • Mark Wilcox, M.D.

    Professor of Medical Microbiology, University of Leeds, and Consultant Clinical Microbiologist, Leeds Teaching Hospitals NHS Trust

Partners

  • Seres’ partnership with Nestlé Health Science, announced Jan. 11, 2016, pertains to C. difficile and IBD programs for markets outside of North America.

  • Seres is partnering with the University of Texas MD Anderson Cancer Center and the Parker Institute for Cancer Immunotherapy, as announced Nov. 14, 2017, to develop microbiome therapies to improve the outcomes of cancer patients.

  • Seres’ collaboration with AstraZeneca, announced Mar. 11, 2019, aims to advance the mechanistic understanding of the microbiome’s role in the efficacy of cancer immunotherapy, including potential synergy with AstraZeneca compounds.

  • Seres is partnering with CARB-X, as announced Nov. 7, 2017, and Memorial Sloan Kettering Cancer Center, as announced May 12, 2016, to progress the development of microbiome therapeutics to prevent serious bacterial infections and graft versus host disease in patients undergoing transplantation.

Our latest
news

08/10/2020

Seres Announces Positive Topline Results for SER-109
SER-109 met primary endpoint in Phase 3 study in C. difficile

READ MORE